<!DOCTYPE html>
<html lang="en">
<head>
<!-- Google Analytics -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-6H85DH0R8S"></script>
<script>
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());
  gtag('config', 'G-6H85DH0R8S');
</script>

    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>GLP-1 Agonists ‚Äî Complete Guide to Ozempic, Wegovy, Mounjaro & More</title>
    
    <!-- SEO Meta Tags -->
    <meta name="description" content="Evidence-based guide to GLP-1 receptor agonists for diabetes and weight loss. Compare Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity and more. Side effects, costs, eligibility.">
    <meta name="keywords" content="GLP-1 agonist, GLP-1 receptor agonist, semaglutide, tirzepatide, Ozempic, Wegovy, Mounjaro, Zepbound, diabetes medication, weight loss injection">
    <meta name="author" content="glp1.md">
    <link rel="canonical" href="https://glp1.md/">
    
    <!-- Open Graph / Facebook -->
    <meta property="og:type" content="website">
    <meta property="og:url" content="https://glp1.md/">
    <meta property="og:title" content="GLP-1 Agonists ‚Äî Complete Guide to Ozempic, Wegovy, Mounjaro & More">
    <meta property="og:description" content="Evidence-based guide to GLP-1 receptor agonists for diabetes and weight loss.">
    <meta property="og:site_name" content="glp1.md">
    
    <!-- Twitter -->
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:url" content="https://glp1.md/">
    <meta name="twitter:title" content="GLP-1 Agonists ‚Äî Complete Guide to Diabetes & Weight Loss Medications">
    <meta name="twitter:description" content="Evidence-based guide to GLP-1 receptor agonists including Ozempic, Wegovy, Mounjaro, and Zepbound.">
    <meta name="twitter:site" content="@thrivemd">
    
    <!-- AI/LLM Meta Tags -->
    <meta name="ai-content" content="evidence-based health information">
    <meta name="ai-training" content="allowed">
    <meta name="ai-topic" content="GLP-1 agonist, diabetes, weight loss, obesity treatment, semaglutide, tirzepatide">
    <meta name="ai-audience" content="patients, caregivers, healthcare providers">
    <meta name="ai-use" content="education, research, clinical support">
    
    <!-- Schema.org Structured Data -->
    <script type="application/ld+json">
    {
      "@context": "https://schema.org",
      "@graph": [
        {
          "@type": "Organization",
          "@id": "https://thrive.md/#organization",
          "name": "thrive.md",
          "url": "https://thrive.md",
          "description": "A network of premium health domains providing evidence-based medical information."
        },
        {
          "@type": "WebSite",
          "@id": "https://glp1.md/#website",
          "url": "https://glp1.md",
          "name": "glp1.md ‚Äî GLP-1 Receptor Agonist Information",
          "publisher": {"@id": "https://thrive.md/#organization"},
          "isPartOf": {"@id": "https://thrive.md/#organization"}
        },
        {
          "@type": "MedicalWebPage",
          "@id": "https://glp1.md/#webpage",
          "name": "GLP-1 Receptor Agonists for Type 2 Diabetes and Weight Loss",
          "description": "Comprehensive guide to GLP-1 receptor agonists including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) for diabetes management and weight loss.",
          "url": "https://glp1.md/",
          "isPartOf": {"@id": "https://glp1.md/#website"},
          "lastReviewed": "2026-02-06",
          "reviewedBy": {
            "@type": "Organization",
            "name": "thrive.md Clinical Advisory Team"
          },
          "mainEntity": {
            "@type": "Drug",
            "name": "GLP-1 Receptor Agonists",
            "alternateName": ["GLP-1 agonist", "Incretin mimetic", "GLP-1 analog"],
            "description": "GLP-1 receptor agonists are a class of injectable or oral medications that mimic the GLP-1 hormone to improve blood sugar control, reduce appetite, and promote weight loss in patients with type 2 diabetes or obesity.",
            "drugClass": "GLP-1 receptor agonist",
            "clinicalPharmacology": "GLP-1 receptor agonists enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite through central nervous system effects.",
            "indication": "Type 2 diabetes mellitus, chronic weight management (obesity), cardiovascular risk reduction",
            "contraindication": "History of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), hypersensitivity to the specific GLP-1 agonist"
          },
          "speakable": {
            "@type": "SpeakableSpecification",
            "cssSelector": ["h1", ".stat-number", ".hero-subtitle"]
          }
        },
        {
          "@type": "FAQPage",
          "@id": "https://glp1.md/#faq",
          "mainEntity": [
            {
              "@type": "Question",
              "name": "What is a GLP-1 agonist?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "A GLP-1 agonist (glucagon-like peptide-1 receptor agonist) is a class of medications that mimic the hormone GLP-1. These drugs enhance insulin secretion when blood sugar is high, reduce glucagon release, slow stomach emptying, and reduce appetite. They are FDA-approved for type 2 diabetes and, in some formulations, for chronic weight management. Common examples include Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, and Victoza."
              }
            },
            {
              "@type": "Question",
              "name": "What is the difference between Ozempic and Wegovy?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "Ozempic and Wegovy contain the same active ingredient (semaglutide) made by the same manufacturer (Novo Nordisk). The key difference is indication and dose: Ozempic is FDA-approved for type 2 diabetes (max dose 2 mg weekly), while Wegovy is FDA-approved for chronic weight management (max dose 2.4 mg weekly). They are essentially the same medication at different doses for different purposes."
              }
            },
            {
              "@type": "Question",
              "name": "How much weight can you lose on GLP-1 medications?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "Weight loss varies by medication and individual. Clinical trials show: Ozempic (2 mg): 12-14 lbs average; Wegovy (2.4 mg): 15-17% of body weight (about 35 lbs for a 200 lb person); Mounjaro (15 mg): up to 22-25% of body weight in trials; Zepbound (15 mg): 20-22% of body weight. Results depend on diet, exercise, starting weight, and individual response."
              }
            },
            {
              "@type": "Question",
              "name": "Are GLP-1 agonists covered by insurance?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "Coverage varies significantly. For type 2 diabetes: Most commercial insurance plans cover GLP-1 medications with prior authorization; copays range from $25-$300/month. For weight loss: Coverage is more limited‚Äîmany plans exclude weight loss medications. Medicare Part D covers diabetes indications but generally excludes weight loss. Manufacturer savings programs can reduce costs to $25-$150/month for eligible patients."
              }
            },
            {
              "@type": "Question",
              "name": "What are the most common side effects of GLP-1 medications?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "The most common side effects are gastrointestinal: nausea (15-44%), vomiting (6-27%), diarrhea (9-30%), constipation (6-24%), and abdominal pain (5-20%). These typically improve over 4-8 weeks as the body adjusts. Serious but rare risks include pancreatitis, gallbladder disease, kidney problems, and thyroid tumors (observed in animal studies). Starting at low doses and titrating slowly helps minimize side effects."
              }
            },
            {
              "@type": "Question",
              "name": "Who qualifies for GLP-1 weight loss medications?",
              "acceptedAnswer": {
                "@type": "Answer",
                "text": "FDA criteria for weight loss GLP-1 medications (Wegovy, Zepbound): Adults with BMI ‚â•30 (obesity), OR BMI ‚â•27 with at least one weight-related condition such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea. Adolescents 12+ with BMI at the 95th percentile or higher may qualify for Wegovy. Your doctor will evaluate your medical history to determine if you're a candidate."
              }
            }
          ]
        }
      ]
    }
    </script>
    
    <link rel="icon" type="image/svg+xml" href="data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 32 32'%3E%3Ctext x='16' y='24' font-family='-apple-system,system-ui,sans-serif' font-weight='800' font-size='16' fill='%230d9488' text-anchor='middle' letter-spacing='-0.5'%3E.md%3C/text%3E%3C/svg%3E">
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link href="https://fonts.googleapis.com/css2?family=Source+Serif+4:wght@400;500;600;700&family=Inter:wght@400;500;600&display=swap" rel="stylesheet">
    <style>
        :root {
            --bg-primary: #ffffff;
            --bg-secondary: #f8fafc;
            --bg-tertiary: #f1f5f9;
            --text-primary: #0f172a;
            --text-secondary: #475569;
            --text-muted: #94a3b8;
            --accent: #0d9488;
            --accent-dark: #0f766e;
            --accent-light: #ccfbf1;
            --border: #e2e8f0;
            --font-display: 'Source Serif 4', Georgia, serif;
            --font-body: 'Inter', -apple-system, sans-serif;
        }

        html {
            scroll-behavior: smooth;
        }

        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: var(--font-body);
            background: var(--bg-primary);
            color: var(--text-primary);
            line-height: 1.7;
            font-size: 16px;
            transition: padding 0.4s ease;
        }

        /* Split-screen mode */
        body.split-mode {
            padding-right: 45%;
        }
        body.split-mode header {
            right: 45%;
        }
        body.split-mode .chat-panel {
            position: fixed;
            top: 0;
            right: 0;
            width: 45%;
            height: 100vh;
            background: var(--bg-secondary);
            border-left: 1px solid var(--border);
            display: flex;
            flex-direction: column;
            z-index: 200;
            animation: slideIn 0.4s ease;
        }
        @keyframes slideIn {
            from { transform: translateX(100%); opacity: 0; }
            to { transform: translateX(0); opacity: 1; }
        }
        body.split-mode .chat-panel .chat-header {
            padding: 20px 24px;
            border-bottom: 1px solid var(--border);
            background: var(--bg-primary);
        }
        body.split-mode .chat-panel .chat-messages {
            flex: 1;
            overflow-y: auto;
            padding: 24px;
            padding-bottom: 16px;
            display: block !important;
            min-height: 0;
        }
        body.split-mode .chat-panel .chat-input-area {
            padding: 16px 24px;
            border-top: 1px solid var(--border);
            background: var(--bg-primary);
            flex-shrink: 0;
        }
        body.split-mode .chat-panel .qa-suggestions,
        body.split-mode .chat-panel .chat-note {
            display: none;
        }
        body.split-mode .chat-panel .chat-close {
            display: flex;
        }
        body.split-mode .hero .chat-box {
            display: none;
        }
        .chat-close {
            display: none;
            position: absolute;
            top: 16px;
            right: 16px;
            width: 32px;
            height: 32px;
            border: none;
            background: var(--bg-tertiary);
            border-radius: 8px;
            cursor: pointer;
            align-items: center;
            justify-content: center;
            font-size: 18px;
            color: var(--text-muted);
            transition: all 0.2s;
        }
        .chat-close:hover {
            background: var(--border);
            color: var(--text-primary);
        }
        @media (max-width: 900px) {
            body.split-mode { padding-right: 0; }
            body.split-mode header { right: 0; }
            body.split-mode .chat-panel { width: 100%; }
            body.split-mode .chat-panel .chat-messages {
                padding-bottom: env(safe-area-inset-bottom, 16px);
            }
        }

        /* Header */
        header {
            position: fixed;
            top: 0;
            left: 0;
            right: 0;
            z-index: 100;
            background: rgba(255, 255, 255, 0.95);
            backdrop-filter: blur(10px);
            border-bottom: 1px solid var(--border);
        }

        .header-inner {
            max-width: 1100px;
            margin: 0 auto;
            padding: 16px 24px;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        .logo {
            font-family: var(--font-display);
            font-size: 22px;
            font-weight: 600;
            color: var(--text-primary);
            text-decoration: none;
        }

        .logo span {
            color: var(--accent);
        }

        nav {
            display: flex;
            gap: 32px;
        }

        nav a {
            color: var(--text-secondary);
            text-decoration: none;
            font-size: 14px;
            font-weight: 500;
            transition: color 0.2s;
        }

        nav a:hover {
            color: var(--accent);
        }

        /* Hero */
        .hero {
            padding: 140px 24px 80px;
            max-width: 720px;
            margin: 0 auto;
        }

        .hero-eyebrow {
            font-size: 13px;
            font-weight: 600;
            color: var(--accent);
            text-transform: uppercase;
            letter-spacing: 1px;
            margin-bottom: 16px;
        }

        h1 {
            font-family: var(--font-display);
            font-size: clamp(36px, 5vw, 48px);
            font-weight: 700;
            line-height: 1.2;
            margin-bottom: 20px;
            color: var(--text-primary);
        }

        .hero-subtitle {
            font-size: 19px;
            color: var(--text-secondary);
            line-height: 1.7;
            margin-bottom: 40px;
        }

        /* Chat Box */
        .chat-box {
            background: var(--bg-secondary);
            border: 1px solid var(--border);
            border-radius: 12px;
            overflow: hidden;
        }

        .chat-header {
            padding: 16px 20px;
            border-bottom: 1px solid var(--border);
            display: flex;
            align-items: center;
            gap: 12px;
        }

        .chat-status {
            width: 10px;
            height: 10px;
            background: var(--accent);
            border-radius: 50%;
        }

        .chat-header-text {
            font-size: 14px;
            font-weight: 600;
            color: var(--text-primary);
        }

        .chat-header-sub {
            font-size: 12px;
            color: var(--text-muted);
            font-weight: 400;
            margin-left: 8px;
        }

        .chat-messages {
            padding: 20px;
            background: var(--bg-primary);
            min-height: 0;
            max-height: 350px;
            overflow-y: auto;
            display: none;
        }
        .chat-messages.active {
            display: block;
        }
        .chat-messages.active:has(.chat-message) {
            min-height: 80px;
        }

        .chat-message {
            display: flex;
            gap: 12px;
            margin-bottom: 16px;
        }

        .chat-message:last-child {
            margin-bottom: 0;
        }

        .chat-message.user {
            flex-direction: row-reverse;
        }

        .chat-avatar {
            width: 32px;
            height: 32px;
            border-radius: 50%;
            background: var(--bg-tertiary);
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 12px;
            font-weight: 600;
            color: var(--text-muted);
            flex-shrink: 0;
        }

        .chat-message.assistant .chat-avatar {
            background: var(--accent-light);
            color: var(--accent-dark);
        }

        .chat-bubble {
            background: var(--bg-secondary);
            padding: 12px 16px;
            border-radius: 12px;
            border-top-left-radius: 4px;
            max-width: 85%;
            border: 1px solid var(--border);
        }

        .chat-message.user .chat-bubble {
            background: var(--accent);
            color: white;
            border-color: transparent;
            border-top-left-radius: 12px;
            border-top-right-radius: 4px;
        }

        .chat-bubble p {
            font-size: 14px;
            line-height: 1.6;
            color: var(--text-secondary);
        }

        .chat-message.user .chat-bubble p {
            color: white;
        }

        .chat-input-area {
            padding: 16px 20px;
            border-top: 1px solid var(--border);
            display: flex;
            gap: 12px;
        }

        .chat-input {
            flex: 1;
            padding: 12px 16px;
            background: var(--bg-primary);
            border: 1px solid var(--border);
            border-radius: 8px;
            font-size: 14px;
            color: var(--text-primary);
            outline: none;
            transition: border-color 0.2s;
        }

        .chat-input::placeholder {
            color: var(--text-muted);
        }

        .chat-input:focus {
            border-color: var(--accent);
        }

        .chat-send {
            background: var(--accent);
            color: white;
            border: none;
            padding: 12px 20px;
            border-radius: 8px;
            font-weight: 600;
            font-size: 14px;
            cursor: pointer;
            transition: background 0.2s;
        }

        .chat-send:hover {
            background: var(--accent-dark);
        }

        .chat-note {
            font-size: 11px;
            color: var(--text-muted);
            padding: 12px 20px;
            background: var(--bg-tertiary);
            text-align: center;
        }

        .qa-suggestions {
            padding: 8px 16px 12px;
            display: flex;
            gap: 8px;
            flex-wrap: wrap;
        }

        .qa-suggestions span {
            background: var(--bg-primary);
            border: 1px solid var(--border);
            border-radius: 100px;
            padding: 6px 16px;
            font-size: 13px;
            color: var(--text-secondary);
            cursor: pointer;
            transition: all 0.2s;
        }

        .qa-suggestions span:hover {
            border-color: var(--accent);
            color: var(--accent);
            background: var(--accent-light);
        }

        /* Stats Bar */
        .stats-bar {
            background: var(--bg-secondary);
            border-top: 1px solid var(--border);
            border-bottom: 1px solid var(--border);
            padding: 48px 24px;
        }

        .stats-inner {
            max-width: 1100px;
            margin: 0 auto;
            display: grid;
            grid-template-columns: repeat(4, 1fr);
            gap: 32px;
        }

        .stat {
            text-align: center;
        }

        .stat-number {
            font-family: var(--font-display);
            font-size: 36px;
            font-weight: 700;
            color: var(--text-primary);
            margin-bottom: 4px;
        }

        .stat-label {
            font-size: 14px;
            color: var(--text-secondary);
            line-height: 1.4;
        }

        .stat-source {
            font-size: 11px;
            color: var(--text-muted);
            margin-top: 4px;
        }

        /* Main Content */
        main {
            max-width: 720px;
            margin: 0 auto;
            padding: 64px 24px;
        }

        .section {
            margin-bottom: 64px;
        }

        .section-label {
            font-size: 12px;
            font-weight: 600;
            color: var(--accent);
            text-transform: uppercase;
            letter-spacing: 1px;
            margin-bottom: 12px;
        }

        h2 {
            font-family: var(--font-display);
            font-size: 28px;
            font-weight: 700;
            margin-bottom: 20px;
            color: var(--text-primary);
        }

        .section > p {
            font-size: 17px;
            color: var(--text-secondary);
            margin-bottom: 20px;
        }

        /* Comparison Table */
        .comparison-table {
            width: 100%;
            border-collapse: collapse;
            margin: 32px 0;
            border: 1px solid var(--border);
            border-radius: 8px;
            overflow: hidden;
        }

        .comparison-table thead {
            background: var(--bg-secondary);
        }

        .comparison-table th {
            padding: 12px 16px;
            text-align: left;
            font-size: 13px;
            font-weight: 600;
            color: var(--text-primary);
            border-bottom: 1px solid var(--border);
        }

        .comparison-table td {
            padding: 12px 16px;
            font-size: 14px;
            color: var(--text-secondary);
            border-bottom: 1px solid var(--border);
        }

        .comparison-table tr:last-child td {
            border-bottom: none;
        }

        .comparison-table tr:hover {
            background: var(--bg-secondary);
        }

        /* Medication Cards */
        .med-grid {
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 24px;
            margin: 32px 0;
        }

        .med-card {
            background: var(--bg-secondary);
            border: 1px solid var(--border);
            border-radius: 12px;
            padding: 24px;
            transition: border-color 0.2s;
        }

        .med-card:hover {
            border-color: var(--accent);
        }

        .med-card h3 {
            font-family: var(--font-display);
            font-size: 20px;
            font-weight: 700;
            margin-bottom: 4px;
            color: var(--text-primary);
        }

        .med-card .generic {
            font-size: 13px;
            color: var(--text-muted);
            margin-bottom: 12px;
        }

        .med-card .indication {
            display: inline-block;
            background: var(--accent-light);
            color: var(--accent-dark);
            font-size: 11px;
            font-weight: 600;
            padding: 4px 10px;
            border-radius: 100px;
            margin-bottom: 12px;
        }

        .med-card p {
            font-size: 14px;
            color: var(--text-secondary);
            line-height: 1.6;
        }

        /* Warning Box */
        .warning-box {
            background: #fef2f2;
            border: 1px solid #fecaca;
            border-left: 4px solid #ef4444;
            border-radius: 8px;
            padding: 20px;
            margin: 32px 0;
        }

        .warning-box h3 {
            font-family: var(--font-display);
            font-size: 17px;
            font-weight: 600;
            margin-bottom: 8px;
            color: #991b1b;
        }

        .warning-box p {
            font-size: 14px;
            color: #7f1d1d;
            line-height: 1.6;
            margin-bottom: 0;
        }

        /* Info Box */
        .info-box {
            background: var(--bg-secondary);
            border: 1px solid var(--border);
            border-left: 4px solid var(--accent);
            border-radius: 8px;
            padding: 20px;
            margin: 32px 0;
        }

        .info-box h3 {
            font-family: var(--font-display);
            font-size: 17px;
            font-weight: 600;
            margin-bottom: 8px;
            color: var(--text-primary);
        }

        .info-box p {
            font-size: 14px;
            color: var(--text-secondary);
            line-height: 1.6;
            margin-bottom: 0;
        }

        /* Lists */
        ul, ol {
            margin-left: 24px;
            margin-top: 16px;
            margin-bottom: 16px;
            color: var(--text-secondary);
            line-height: 1.8;
        }

        li {
            margin-bottom: 8px;
        }

        /* Footer */
        footer {
            background: var(--bg-secondary);
            border-top: 1px solid var(--border);
            padding: 48px 24px;
        }

        .footer-inner {
            max-width: 1100px;
            margin: 0 auto;
            display: grid;
            grid-template-columns: 2fr 1fr 1fr 1fr;
            gap: 40px;
        }

        .footer-brand .logo {
            display: inline-block;
            margin-bottom: 12px;
        }

        .footer-brand p {
            font-size: 14px;
            color: var(--text-muted);
            line-height: 1.6;
        }

        .footer-links h4 {
            font-size: 12px;
            font-weight: 600;
            color: var(--text-primary);
            text-transform: uppercase;
            letter-spacing: 0.5px;
            margin-bottom: 12px;
        }

        .footer-links a {
            display: block;
            color: var(--text-muted);
            text-decoration: none;
            font-size: 14px;
            margin-bottom: 8px;
            transition: color 0.2s;
        }

        .footer-links a:hover {
            color: var(--accent);
        }

        .footer-bottom {
            max-width: 1100px;
            margin: 32px auto 0;
            padding-top: 24px;
            border-top: 1px solid var(--border);
            display: flex;
            justify-content: space-between;
            font-size: 13px;
            color: var(--text-muted);
        }

        .last-reviewed {
            font-size: 12px;
            color: var(--text-muted);
            margin-top: 32px;
            padding-top: 16px;
            border-top: 1px solid var(--border);
        }

        /* Responsive */
        @media (max-width: 768px) {
            nav { display: none; }
            .stats-inner { grid-template-columns: repeat(2, 1fr); gap: 24px; }
            .footer-inner { grid-template-columns: 1fr; gap: 24px; }
            .med-grid { grid-template-columns: 1fr; }
            .hero {
                padding: 100px 16px 40px;
            }
            .hero h1 {
                font-size: 32px;
            }
            .hero-subtitle {
                font-size: 17px;
                margin-bottom: 24px;
            }
            .chat-box {
                border-radius: 10px;
            }
            .chat-input-area {
                flex-direction: row !important;
                align-items: flex-end;
                padding: 12px 12px;
                gap: 8px;
            }
            .chat-input-area .chat-input {
                flex: 1;
                border-radius: 20px;
                padding: 10px 16px;
                font-size: 16px;
                min-height: 40px;
            }
            .chat-input-area .chat-send {
                width: 40px;
                height: 40px;
                min-width: 40px;
                border-radius: 50%;
                padding: 0;
                display: flex;
                align-items: center;
                justify-content: center;
                flex-shrink: 0;
            }
            .chat-input-area .chat-send span {
                font-size: 0;
            }
            .chat-input-area .chat-send span::before {
                content: '‚Üë';
                font-size: 20px;
                font-weight: 700;
            }
            .qa-suggestions {
                flex-wrap: nowrap;
                overflow-x: auto;
                -webkit-overflow-scrolling: touch;
                padding-bottom: 4px;
                scrollbar-width: none;
            }
            .qa-suggestions::-webkit-scrollbar { display: none; }
            .qa-suggestions span {
                flex-shrink: 0;
                font-size: 12px;
                padding: 5px 12px;
            }
            .chat-note {
                font-size: 10px;
                padding: 8px 16px;
            }
            .chat-messages {
                max-height: none;
            }
            .comparison-table {
                font-size: 12px;
            }
            .comparison-table th,
            .comparison-table td {
                padding: 8px 10px;
            }
            .footer-bottom {
                flex-direction: column;
                gap: 12px;
                text-align: center;
            }
        }

        @supports (padding-bottom: env(safe-area-inset-bottom)) {
            @media (max-width: 768px) {
                .chat-note {
                    padding-bottom: calc(8px + env(safe-area-inset-bottom));
                }
            }
        }
    </style>
</head>
<body>
    <!-- Split-mode chat panel (hidden initially) -->
    <div class="chat-panel" id="chat-panel" style="display: none;">
        <button class="chat-close" onclick="closeSplitMode()">‚úï</button>
        <div class="chat-header">
            <div class="chat-status"></div>
            <span class="chat-header-text">Ask about GLP-1 medications<span class="chat-header-sub">‚Äî answers from FDA labels & clinical trials</span></span>
        </div>
        <div id="panel-messages" class="chat-messages"></div>
        <div class="chat-input-area">
            <textarea id="panel-input" class="chat-input" placeholder="Ask a follow-up question..." rows="1" style="resize:none;"></textarea>
            <button id="panel-submit" class="chat-send" onclick="askQuestion()">
                <span>Send</span>
            </button>
        </div>
    </div>

    <header>
        <div class="header-inner">
            <a href="/" class="logo">glp1<span>.md</span></a>
            <nav>
                <a href="#ask" onclick="event.preventDefault(); activateSplitMode(); document.getElementById('panel-input').focus();">Ask</a>
                <a href="/comparison.html">Compare Meds</a>
                <a href="/side-effects.html">Side Effects</a>
                <a href="/cost-insurance.html">Cost & Insurance</a>
                <a href="/eligibility.html">Who Qualifies</a>
                <a href="/faq.html">FAQ</a>
                <a href="/blog/">Articles</a>
            </nav>
        </div>
    </header>

    <section class="hero">
        <div class="hero-eyebrow">GLP-1 Medication Guide</div>
        <h1>GLP-1 Agonists for Diabetes & Weight Loss</h1>
        <p class="hero-subtitle">GLP-1 receptor agonists are a class of injectable medications that help control blood sugar, reduce appetite, and promote significant weight loss. Compare Ozempic, Wegovy, Mounjaro, Zepbound and more ‚Äî all in one place.</p>
        
        <div class="chat-box" id="ask">
            <div class="chat-header">
                <div class="chat-status"></div>
                <span class="chat-header-text">Ask about GLP-1 medications<span class="chat-header-sub">‚Äî answers from FDA labels & clinical trials</span></span>
            </div>
            <div id="chat-messages" class="chat-messages active">
                <div class="chat-message assistant">
                    <div class="chat-avatar">MD</div>
                    <div class="chat-bubble"><p>I can answer questions about GLP-1 medications based on FDA-approved prescribing information and clinical trial data. Ask me about specific medications, side effects, or how they compare to each other.</p></div>
                </div>
            </div>
            <div class="chat-input-area">
                <textarea id="qa-input" class="chat-input" placeholder="Ask about GLP-1 medications..." rows="1" style="resize:none;"></textarea>
                <button id="qa-submit" class="chat-send" onclick="askQuestion()">
                    <span>Send</span>
                </button>
            </div>
            <div id="qa-suggestions" class="qa-suggestions">
                <span onclick="askSuggestion(this)">Ozempic vs Mounjaro?</span>
                <span onclick="askSuggestion(this)">Which has fewest side effects?</span>
                <span onclick="askSuggestion(this)">Do I qualify for Wegovy?</span>
            </div>
            <div class="chat-note">Answers based on FDA-approved labeling and peer-reviewed clinical trials. Always consult your healthcare provider before starting any medication.</div>
        </div>
    </section>

    <section class="stats-bar">
        <div class="stats-inner">
            <div class="stat">
                <div class="stat-number">15-25%</div>
                <div class="stat-label">Body weight loss with tirzepatide</div>
                <div class="stat-source">SURMOUNT trials</div>
            </div>
            <div class="stat">
                <div class="stat-number">40M+</div>
                <div class="stat-label">Americans prescribed GLP-1 medications</div>
                <div class="stat-source">IQVIA, 2025</div>
            </div>
            <div class="stat">
                <div class="stat-number">20%</div>
                <div class="stat-label">CV event reduction (MACE)</div>
                <div class="stat-source">SELECT trial, 2023</div>
            </div>
            <div class="stat">
                <div class="stat-number">$900-1,300</div>
                <div class="stat-label">Monthly cost without insurance</div>
                <div class="stat-source">GoodRx, 2026</div>
            </div>
        </div>
    </section>

    <main>
        <div class="warning-box">
            <h3>‚ö†Ô∏è Important Safety Information</h3>
            <p><strong>Boxed Warning:</strong> GLP-1 medications carry a risk of thyroid C-cell tumors based on animal studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Discuss your full medical history with your healthcare provider.</p>
        </div>

        <section class="section">
            <div class="section-label">Overview</div>
            <h2>What are GLP-1 Agonists?</h2>
            <p>GLP-1 receptor agonists (also called GLP-1 RAs or incretin mimetics) are a class of medications that mimic the naturally occurring hormone glucagon-like peptide-1. When you eat, your gut releases GLP-1, which signals your pancreas to produce insulin. GLP-1 medications amplify this effect and provide additional benefits:</p>
            <ul>
                <li><strong>Enhanced insulin secretion</strong> ‚Äî Only when blood sugar is elevated, minimizing hypoglycemia risk</li>
                <li><strong>Reduced glucagon release</strong> ‚Äî Prevents your liver from dumping excess sugar into your blood</li>
                <li><strong>Slowed gastric emptying</strong> ‚Äî Food stays in your stomach longer, helping you feel full</li>
                <li><strong>Appetite suppression</strong> ‚Äî Acts on brain receptors to reduce hunger and cravings</li>
                <li><strong>Cardiovascular protection</strong> ‚Äî Several GLP-1 medications reduce heart attack and stroke risk</li>
            </ul>
            <p>The result: better blood sugar control, significant weight loss, and reduced cardiovascular risk ‚Äî making GLP-1 medications some of the most impactful advances in diabetes and obesity treatment in decades.</p>
        </section>

        <section class="section">
            <div class="section-label">FDA-Approved Medications</div>
            <h2>Available GLP-1 Medications</h2>
            <p>There are currently several FDA-approved GLP-1 receptor agonists on the market. Some are approved only for type 2 diabetes, while others have additional approvals for weight management or cardiovascular risk reduction.</p>
            
            <div class="med-grid">
                <div class="med-card">
                    <h3>Ozempic</h3>
                    <div class="generic">semaglutide ¬∑ Novo Nordisk</div>
                    <span class="indication">Type 2 Diabetes</span>
                    <p>Once-weekly injection. Doses: 0.25mg, 0.5mg, 1mg, 2mg. Average weight loss: 12-14 lbs. Also reduces CV events.</p>
                </div>
                <div class="med-card">
                    <h3>Wegovy</h3>
                    <div class="generic">semaglutide ¬∑ Novo Nordisk</div>
                    <span class="indication">Weight Loss</span>
                    <p>Once-weekly injection at higher dose (2.4mg). Average weight loss: 15-17% of body weight. SELECT trial showed 20% CV risk reduction.</p>
                </div>
                <div class="med-card">
                    <h3>Mounjaro</h3>
                    <div class="generic">tirzepatide ¬∑ Eli Lilly</div>
                    <span class="indication">Type 2 Diabetes</span>
                    <p>Dual GIP/GLP-1 agonist. Once-weekly. Doses up to 15mg. Highest A1C reduction (up to 2.5%) and weight loss in its class.</p>
                </div>
                <div class="med-card">
                    <h3>Zepbound</h3>
                    <div class="generic">tirzepatide ¬∑ Eli Lilly</div>
                    <span class="indication">Weight Loss</span>
                    <p>Same as Mounjaro, approved for obesity. Average weight loss: 20-22% of body weight. Most potent weight loss medication available.</p>
                </div>
                <div class="med-card">
                    <h3>Trulicity</h3>
                    <div class="generic">dulaglutide ¬∑ Eli Lilly</div>
                    <span class="indication">Type 2 Diabetes</span>
                    <p>Once-weekly injection. Established option since 2014. Moderate weight loss (4-8 lbs). Good tolerability profile.</p>
                </div>
                <div class="med-card">
                    <h3>Rybelsus</h3>
                    <div class="generic">oral semaglutide ¬∑ Novo Nordisk</div>
                    <span class="indication">Type 2 Diabetes</span>
                    <p>Only oral GLP-1 option. Daily tablet taken on empty stomach. Max dose 14mg. Lower weight loss than injectable.</p>
                </div>
            </div>
            <p style="font-size: 14px; color: var(--text-muted);">Other GLP-1 options include Victoza (liraglutide, daily injection), Saxenda (liraglutide for weight loss), and Byetta/Bydureon (exenatide).</p>
        </section>

        <section class="section">
            <div class="section-label">Head-to-Head Comparison</div>
            <h2>How do GLP-1 medications compare?</h2>
            <table class="comparison-table">
                <thead>
                    <tr>
                        <th>Medication</th>
                        <th>Frequency</th>
                        <th>Max Dose</th>
                        <th>A1C Reduction</th>
                        <th>Weight Loss</th>
                        <th>Cost/Month</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>Ozempic</strong></td>
                        <td>Weekly</td>
                        <td>2 mg</td>
                        <td>1.5-1.8%</td>
                        <td>12-14 lbs</td>
                        <td>$935</td>
                    </tr>
                    <tr>
                        <td><strong>Wegovy</strong></td>
                        <td>Weekly</td>
                        <td>2.4 mg</td>
                        <td>1.5%*</td>
                        <td>15-17%</td>
                        <td>$1,349</td>
                    </tr>
                    <tr>
                        <td><strong>Mounjaro</strong></td>
                        <td>Weekly</td>
                        <td>15 mg</td>
                        <td>2.0-2.5%</td>
                        <td>15-25 lbs</td>
                        <td>$1,023</td>
                    </tr>
                    <tr>
                        <td><strong>Zepbound</strong></td>
                        <td>Weekly</td>
                        <td>15 mg</td>
                        <td>2.0%*</td>
                        <td>20-22%</td>
                        <td>$1,060</td>
                    </tr>
                    <tr>
                        <td><strong>Trulicity</strong></td>
                        <td>Weekly</td>
                        <td>4.5 mg</td>
                        <td>1.0-1.5%</td>
                        <td>4-8 lbs</td>
                        <td>$970</td>
                    </tr>
                    <tr>
                        <td><strong>Rybelsus</strong></td>
                        <td>Daily (oral)</td>
                        <td>14 mg</td>
                        <td>1.0-1.4%</td>
                        <td>6-10 lbs</td>
                        <td>$935</td>
                    </tr>
                    <tr>
                        <td><strong>Victoza</strong></td>
                        <td>Daily</td>
                        <td>1.8 mg</td>
                        <td>1.0-1.5%</td>
                        <td>6-10 lbs</td>
                        <td>$987</td>
                    </tr>
                </tbody>
            </table>
            <p style="font-size: 13px; color: var(--text-muted); margin-top: 12px;">*Weight loss formulations (Wegovy, Zepbound) studied in non-diabetic populations. Prices are average cash prices without insurance from GoodRx (February 2026). Individual results and costs vary.</p>
        </section>

        <section class="section">
            <div class="section-label">Mechanism</div>
            <h2>How do GLP-1 agonists work?</h2>
            <p>GLP-1 medications work through multiple pathways to improve metabolic health:</p>
            
            <h3 style="font-family: var(--font-display); font-size: 19px; margin-top: 24px; margin-bottom: 12px;">1. Pancreas: Smart Insulin Release</h3>
            <p>Unlike older diabetes medications, GLP-1 agonists are "glucose-dependent" ‚Äî they only stimulate insulin release when blood sugar is actually elevated. This dramatically reduces the risk of hypoglycemia (low blood sugar) compared to sulfonylureas or insulin.</p>
            
            <h3 style="font-family: var(--font-display); font-size: 19px; margin-top: 24px; margin-bottom: 12px;">2. Liver: Glucagon Suppression</h3>
            <p>GLP-1 medications suppress the release of glucagon, the hormone that tells your liver to release stored sugar. This prevents the blood sugar spikes that occur between meals and overnight.</p>
            
            <h3 style="font-family: var(--font-display); font-size: 19px; margin-top: 24px; margin-bottom: 12px;">3. Stomach: Delayed Emptying</h3>
            <p>Food stays in your stomach longer, which slows the absorption of glucose and creates prolonged feelings of fullness. This is why many patients experience reduced appetite and eat smaller portions naturally.</p>
            
            <h3 style="font-family: var(--font-display); font-size: 19px; margin-top: 24px; margin-bottom: 12px;">4. Brain: Appetite Control</h3>
            <p>GLP-1 receptors in the hypothalamus are involved in satiety signaling. GLP-1 medications act on these receptors to reduce hunger, decrease food cravings, and change food preferences (many patients report reduced desire for high-fat and high-sugar foods).</p>

            <div class="info-box">
                <h3>üí° Tirzepatide: The Dual Agonist</h3>
                <p>Mounjaro and Zepbound contain tirzepatide, which activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. This dual action appears to provide superior blood sugar control and weight loss compared to GLP-1-only medications, though it may also increase certain side effects.</p>
            </div>
        </section>

        <section class="section">
            <div class="section-label">Clinical Evidence</div>
            <h2>What do the clinical trials show?</h2>
            <p>GLP-1 medications have been extensively studied in large clinical trials. Here are the key findings:</p>
            
            <h3 style="font-family: var(--font-display); font-size: 19px; margin-top: 24px; margin-bottom: 12px;">SUSTAIN Trials (Semaglutide/Ozempic)</h3>
            <p>Over 8,000 patients studied. Key findings: 1.5% A1C reduction at 2 mg dose, 26% reduction in major cardiovascular events (SUSTAIN 6), average weight loss of 12-14 pounds.</p>
            
            <h3 style="font-family: var(--font-display); font-size: 19px; margin-top: 24px; margin-bottom: 12px;">STEP Trials (Semaglutide/Wegovy)</h3>
            <p>Over 4,500 patients with obesity (without diabetes). Key findings: 15-17% body weight loss at 68 weeks, with one-third of patients losing over 20% of their body weight.</p>
            
            <h3 style="font-family: var(--font-display); font-size: 19px; margin-top: 24px; margin-bottom: 12px;">SELECT Trial (Semaglutide CV Outcomes)</h3>
            <p>17,604 patients with obesity and cardiovascular disease but without diabetes. Landmark finding: 20% reduction in heart attack, stroke, and cardiovascular death ‚Äî the first weight loss medication to demonstrate cardiovascular benefit.</p>
            
            <h3 style="font-family: var(--font-display); font-size: 19px; margin-top: 24px; margin-bottom: 12px;">SURMOUNT Trials (Tirzepatide/Mounjaro/Zepbound)</h3>
            <p>Over 5,000 patients studied. Key findings: Up to 22.5% body weight loss at highest dose, with over 60% of patients losing at least 20% of their weight. A1C reductions of 2.0-2.5%, the highest in the class.</p>
            
            <p style="margin-top: 24px;"><strong>Ongoing research:</strong> Clinical trials are investigating GLP-1 medications for sleep apnea, fatty liver disease (NASH/MASH), heart failure with preserved ejection fraction, kidney disease, and even Alzheimer's disease.</p>
        </section>

        <section class="section">
            <div class="section-label">Eligibility</div>
            <h2>Who qualifies for GLP-1 medications?</h2>
            <p>GLP-1 medications are FDA-approved for specific conditions. Your eligibility depends on which medication and which indication:</p>
            
            <h3 style="font-family: var(--font-display); font-size: 19px; margin-top: 24px; margin-bottom: 12px;">For Type 2 Diabetes (Ozempic, Mounjaro, Trulicity, etc.)</h3>
            <ul>
                <li>Adults diagnosed with type 2 diabetes mellitus</li>
                <li>Used as an adjunct to diet and exercise</li>
                <li>May be used alone or with other diabetes medications</li>
                <li>Not recommended as first-line therapy (metformin usually tried first)</li>
            </ul>
            
            <h3 style="font-family: var(--font-display); font-size: 19px; margin-top: 24px; margin-bottom: 12px;">For Weight Loss (Wegovy, Zepbound)</h3>
            <ul>
                <li><strong>BMI ‚â• 30</strong> (obesity), OR</li>
                <li><strong>BMI ‚â• 27</strong> with at least one weight-related condition:
                    <ul style="margin-top: 8px; margin-bottom: 8px;">
                        <li>Type 2 diabetes</li>
                        <li>High blood pressure (hypertension)</li>
                        <li>High cholesterol (dyslipidemia)</li>
                        <li>Obstructive sleep apnea</li>
                        <li>Cardiovascular disease</li>
                    </ul>
                </li>
                <li><strong>Adolescents 12+</strong> with BMI at 95th percentile or higher (Wegovy only)</li>
            </ul>
            
            <div class="warning-box">
                <h3>‚ö†Ô∏è Who should NOT take GLP-1 medications?</h3>
                <p>GLP-1 agonists are contraindicated in patients with: personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), history of severe allergic reaction to any GLP-1 medication, or during pregnancy/breastfeeding. Tell your doctor about any history of pancreatitis, gallbladder disease, kidney disease, or diabetic retinopathy.</p>
            </div>
        </section>

        <section class="section">
            <div class="section-label">Side Effects</div>
            <h2>Common and serious side effects</h2>
            <p>GLP-1 medications share a similar side effect profile, primarily gastrointestinal. Most side effects improve over time as your body adjusts.</p>
            
            <h3 style="font-family: var(--font-display); font-size: 19px; margin-top: 24px; margin-bottom: 12px;">Common Side Effects (may affect 10-40% of patients)</h3>
            <ul>
                <li><strong>Nausea</strong> ‚Äî Most common, especially during dose escalation. Usually improves after 4-8 weeks.</li>
                <li><strong>Vomiting</strong> ‚Äî More common with tirzepatide; tends to decrease over time.</li>
                <li><strong>Diarrhea</strong> ‚Äî May occur early in treatment.</li>
                <li><strong>Constipation</strong> ‚Äî Can be managed with fiber and hydration.</li>
                <li><strong>Abdominal pain</strong> ‚Äî Usually mild; report severe pain to your doctor.</li>
                <li><strong>Injection site reactions</strong> ‚Äî Redness, swelling, or itching at injection site.</li>
            </ul>
            
            <h3 style="font-family: var(--font-display); font-size: 19px; margin-top: 24px; margin-bottom: 12px;">Serious Side Effects (rare but important)</h3>
            <ul>
                <li><strong>Pancreatitis</strong> ‚Äî Stop medication and seek care for severe abdominal pain radiating to back.</li>
                <li><strong>Gallbladder disease</strong> ‚Äî Rapid weight loss increases gallstone risk.</li>
                <li><strong>Kidney injury</strong> ‚Äî Usually related to dehydration from GI symptoms.</li>
                <li><strong>Diabetic retinopathy complications</strong> ‚Äî Rare; more common with rapid blood sugar improvement.</li>
                <li><strong>Hypoglycemia</strong> ‚Äî Risk increases when combined with insulin or sulfonylureas.</li>
                <li><strong>Thyroid tumors</strong> ‚Äî Observed in rodents; not confirmed in humans. Still contraindicated in MTC/MEN2.</li>
            </ul>
            
            <div class="info-box">
                <h3>üí° Minimizing Side Effects</h3>
                <p>Start at the lowest dose and increase slowly (every 4 weeks). Eat smaller, more frequent meals. Avoid high-fat and fried foods. Stay well hydrated. Don't lie down immediately after eating. If nausea is severe, your doctor may slow down the titration schedule.</p>
            </div>
        </section>

        <section class="section">
            <div class="section-label">Cost & Insurance</div>
            <h2>How much do GLP-1 medications cost?</h2>
            <p>GLP-1 medications are expensive without insurance coverage. Here's what you need to know:</p>
            
            <h3 style="font-family: var(--font-display); font-size: 19px; margin-top: 24px; margin-bottom: 12px;">Cash Prices (without insurance)</h3>
            <ul>
                <li>Ozempic: $900-$1,000/month</li>
                <li>Wegovy: $1,300-$1,400/month</li>
                <li>Mounjaro: $1,000-$1,100/month</li>
                <li>Zepbound: $1,000-$1,100/month</li>
                <li>Trulicity: $900-$1,000/month</li>
            </ul>
            
            <h3 style="font-family: var(--font-display); font-size: 19px; margin-top: 24px; margin-bottom: 12px;">Insurance Coverage</h3>
            <p><strong>For diabetes:</strong> Most commercial insurance plans cover GLP-1 medications with prior authorization. Copays typically range from $25-$300 depending on your plan's formulary tier.</p>
            <p><strong>For weight loss:</strong> Coverage is more limited. Many plans explicitly exclude "weight loss drugs." Check if your plan covers Wegovy or Zepbound for obesity. Some employers are adding coverage due to demonstrated health benefits.</p>
            <p><strong>Medicare:</strong> Part D covers GLP-1 medications for diabetes but generally excludes weight loss indications. This may change as policy evolves.</p>
            
            <h3 style="font-family: var(--font-display); font-size: 19px; margin-top: 24px; margin-bottom: 12px;">Savings Programs</h3>
            <ul>
                <li><strong>Manufacturer savings cards:</strong> Novo Nordisk and Eli Lilly offer programs that can reduce copays to $0-$25 for eligible commercially insured patients.</li>
                <li><strong>Patient assistance programs:</strong> For uninsured or underinsured patients who meet income requirements.</li>
                <li><strong>Compounded semaglutide:</strong> Some pharmacies offer compounded versions at lower cost, though quality and safety vary. The FDA has issued warnings about some compounders.</li>
            </ul>
        </section>

        <section class="section">
            <div class="section-label">Important Considerations</div>
            <h2>What should I discuss with my doctor?</h2>
            <p><strong>GLP-1 medications are prescription medications</strong> that require medical supervision. Before starting, discuss:</p>
            <ul>
                <li>Your complete medical history, especially thyroid cancer, pancreatitis, kidney disease, or diabetic retinopathy</li>
                <li>All medications you're taking, particularly insulin or sulfonylureas (increased hypoglycemia risk)</li>
                <li>Whether you're pregnant, planning pregnancy, or breastfeeding (stop 2 months before conception)</li>
                <li>Your insurance coverage and savings program eligibility</li>
                <li>Realistic expectations ‚Äî these medications work best with lifestyle changes</li>
                <li>Long-term plans ‚Äî weight tends to return if medication is stopped</li>
            </ul>
            <p style="margin-top: 20px;"><strong>This is not medical advice.</strong> Only your healthcare provider can determine if a GLP-1 medication is appropriate for you.</p>
            
            <p class="last-reviewed"><strong>Last reviewed:</strong> February 2026 by the thrive.md Clinical Advisory Team</p>
        </section>

    </main>

    <footer>
        <div class="footer-inner">
            <div class="footer-brand">
                <a href="/" class="logo">glp1<span>.md</span></a>
                <p>Part of the <a href="https://thrive.md" style="color: var(--accent); text-decoration: none;">thrive.md</a> health network. Evidence-based medication information, reviewed by healthcare professionals.</p>
            </div>
            <div class="footer-links">
                <h4>Medications</h4>
                <a href="/comparison.html">Compare All</a>
                <a href="https://ozempic.md">Ozempic</a>
                <a href="https://wegovy.md">Wegovy</a>
                <a href="https://mounjaro.md">Mounjaro</a>
            </div>
            <div class="footer-links">
                <h4>Information</h4>
                <a href="/side-effects.html">Side Effects</a>
                <a href="/cost-insurance.html">Cost & Insurance</a>
                <a href="/eligibility.html">Who Qualifies</a>
                <a href="/faq.html">FAQ</a>
            </div>
            <div class="footer-links">
                <h4>About</h4>
                <a href="https://thrive.md/editorial-policy.html">Editorial Policy</a>
                <a href="https://thrive.md/medical-review.html">Medical Review</a>
                <a href="mailto:hello@thrive.md">Contact</a>
            </div>
        </div>
        <div class="footer-bottom">
            <p>¬© 2026 glp1.md ¬∑ A <a href="https://thrive.md" style="color: var(--text-muted); text-decoration: none;">thrive.md</a> property</p>
            <p><strong>Medical Disclaimer:</strong> This site provides information, not medical advice. Always consult your healthcare provider.</p>
        </div>
    </footer>

    <script>
        const QA_API = 'https://md-qa.md-health.workers.dev/ask';
        const SESSION_ID = localStorage.getItem('md_uid') || (() => { const id = 'u_' + crypto.randomUUID(); localStorage.setItem('md_uid', id); return id; })();
        const TOPIC = 'glp1';
        
        let splitModeActive = false;
        
        function getActiveMessagesDiv() {
            return splitModeActive 
                ? document.getElementById('panel-messages')
                : document.getElementById('chat-messages');
        }
        
        function getActiveInput() {
            return splitModeActive
                ? document.getElementById('panel-input')
                : document.getElementById('qa-input');
        }
        
        function activateSplitMode() {
            if (splitModeActive) return;
            splitModeActive = true;
            
            document.body.classList.add('split-mode');
            const panel = document.getElementById('chat-panel');
            panel.style.display = 'flex';
            
            const heroMessages = document.getElementById('chat-messages');
            const panelMessages = document.getElementById('panel-messages');
            panelMessages.innerHTML = heroMessages.innerHTML;
            panelMessages.classList.add('active');
            
            document.getElementById('panel-input').focus();
            window.scrollTo({ top: 0, behavior: 'smooth' });
        }
        
        function closeSplitMode() {
            splitModeActive = false;
            document.body.classList.remove('split-mode');
            document.getElementById('chat-panel').style.display = 'none';
            
            const panelMessages = document.getElementById('panel-messages');
            const heroMessages = document.getElementById('chat-messages');
            heroMessages.innerHTML = panelMessages.innerHTML;
            heroMessages.classList.add('active');
        }

        function addMessage(text, isUser = false) {
            const messagesDiv = getActiveMessagesDiv();
            messagesDiv.classList.add('active');
            
            const msgDiv = document.createElement('div');
            msgDiv.className = `chat-message ${isUser ? 'user' : 'assistant'}`;
            msgDiv.innerHTML = `
                <div class="chat-avatar">${isUser ? 'You' : 'MD'}</div>
                <div class="chat-bubble"><p>${text}</p></div>
            `;
            
            messagesDiv.appendChild(msgDiv);
            messagesDiv.scrollTop = messagesDiv.scrollHeight;
            return msgDiv;
        }

        async function askQuestion() {
            const input = getActiveInput();
            const question = input.value.trim();
            
            if (!question) return;
            
            const suggestions = document.getElementById('qa-suggestions');
            if (suggestions) suggestions.style.display = 'none';
            
            addMessage(question, true);
            input.value = '';
            
            if (!splitModeActive) {
                activateSplitMode();
            }
            
            const responseMsg = addMessage('Thinking...');
            
            try {
                const res = await fetch(QA_API, {
                    method: 'POST',
                    headers: { 'Content-Type': 'application/json' },
                    body: JSON.stringify({ question, topic: TOPIC, sessionId: SESSION_ID }),
                });
                
                if (!res.ok) {
                    const error = await res.json();
                    throw new Error(error.error || 'Request failed');
                }
                
                // Smooth streaming with typewriter effect
                const reader = res.body.getReader();
                const decoder = new TextDecoder();
                let fullResponse = '';
                let fullText = '';
                let displayedText = '';
                let renderQueue = [];
                let isRendering = false;
                const CHARS_PER_TICK = 3;
                const TICK_MS = 16;
                
                function renderLoop() {
                    if (renderQueue.length === 0) {
                        isRendering = false;
                        return;
                    }
                    const batch = renderQueue.splice(0, CHARS_PER_TICK).join('');
                    displayedText += batch;
                    responseMsg.querySelector('p').textContent = displayedText;
                    getActiveMessagesDiv().scrollTop = getActiveMessagesDiv().scrollHeight;
                    requestAnimationFrame(() => setTimeout(renderLoop, TICK_MS));
                }
                
                function queueText(text) {
                    for (const char of text) {
                        renderQueue.push(char);
                    }
                    if (!isRendering) {
                        isRendering = true;
                        renderLoop();
                    }
                }
                
                while (true) {
                    const { done, value } = await reader.read();
                    if (done) break;
                    
                    const chunk = decoder.decode(value);
                    const lines = chunk.split('\n');
                    
                    for (const line of lines) {
                        if (line.startsWith('data: ')) {
                            const data = line.slice(6);
                            if (data === '[DONE]') continue;
                            
                            try {
                                const parsed = JSON.parse(data);
                                if (parsed.text) {
                                    fullText += parsed.text;
                                    queueText(parsed.text);
                                }
                            } catch (e) {}
                        }
                    }
                }
                
                
                // Track query (client-side)
                fetch('https://mikes-mac-mini.platy-paradise.ts.net:18791/api/track', {
                    method: 'POST',
                    headers: { 'Content-Type': 'application/json', 'X-API-Key': '3460683416d20694dc8f05cdb01af378' },
                    body: JSON.stringify({ site: 'glp1.md', query: question, response: (fullText || fullResponse || '').slice(0, 500), session_id: SESSION_ID || null }),
                }).catch(() => {});
                // GA4 engagement events (reduces bounce rate)
                if (typeof gtag === 'function') {
                  gtag('event', 'qa_question_asked', { event_category: 'Q&A', event_label: 'glp1.md', value: 1 });
                  gtag('event', 'qa_response_received', { event_category: 'Q&A', event_label: 'glp1.md', engagement_time_msec: 10000 });
                }

                await new Promise(resolve => {
                    const checkDone = () => {
                        if (renderQueue.length === 0 && !isRendering) {
                            resolve();
                        } else {
                            setTimeout(checkDone, 50);
                        }
                    };
                    checkDone();
                });
                
                const formatted = fullText.replace(/\[([^\]]+)\]\(([^)]+)\)/g, '<a href="$2" target="_blank" rel="noopener">$1</a>');
                responseMsg.querySelector('p').innerHTML = formatted;
                
            } catch (err) {
                responseMsg.querySelector('p').innerHTML = `<span style="color: #ef4444;">Sorry, something went wrong.</span>`;
            }
            
            getActiveMessagesDiv().scrollTop = getActiveMessagesDiv().scrollHeight;
        }
        
        function askSuggestion(el) {
            document.getElementById('qa-input').value = el.textContent;
            askQuestion();
        }
        
        document.getElementById('qa-input').addEventListener('keydown', (e) => {
            if (e.key === 'Enter' && !e.shiftKey) {
                e.preventDefault();
                askQuestion();
            }
        });
        
        document.getElementById('panel-input').addEventListener('keydown', (e) => {
            if (e.key === 'Enter' && !e.shiftKey) {
                e.preventDefault();
                askQuestion();
            }
        });
    </script>
</body>
</html>
